Inhaled GSK3008348
Idiopathic Pulmonary Fibrosis · Inhaled integrin αvβ6 inhibitor — targets TGF-β activation on AEC2s
Mechanism
Inhaled integrin αvβ6 inhibitor — targets TGF-β activation on AEC2s
Development stage
Phase II
Evidence level
Level 2 (Phase II)
Developer
GSK / UCSF
Overview
Inhaled delivery targets exact cells expressing αvβ6. Better lung specificity vs systemic PLN-74809.
Explore related
Medical disclaimer. This page summarizes research about Inhaled GSK3008348 for information only. It is not medical advice. Verify approval status and evidence with the FDA and a pulmonologist.